SCHEMBL2178453

SCHEMBL2178453

CC(C)[C@@H](C(=O)O)N1Cc2cc(-c3ccc(NC(=O)Nc4cccc(C#N)c4)cc3)ccc2C1=O

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
KDR P35968 1/20 0.47
MCHR1 Q99705 3/20 0.43
SDCBP O00560 3/20 0.42
SDC2 P34741 3/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
KIT P10721 1/20 0.42
PDGFRA P16234 1/20 0.42
NAMPT P43490 1/20 0.40
GPR142 Q7Z601 1/20 0.40
CCKBR P32239 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2178135 1.00 MEN1 (0.47) MEN1ALDH1A1MAPTKMT2AKDR
SCHEMBL2179408 0.93 KDR (0.52) MEN1ALDH1A1MAPTKMT2AKDR
SCHEMBL2177431 0.93 KDR (0.52) MEN1ALDH1A1MAPTKMT2AKDR
SCHEMBL2177643 0.92 SDCBP (0.46) MEN1ALDH1A1MAPTKMT2ASDCBP
SCHEMBL2177634 0.92 SDCBP (0.46) MEN1ALDH1A1MAPTKMT2ASDCBP
SCHEMBL2181226 0.89 LMNA (0.51) MAPTSDCBPSDC2LMNATP53
SCHEMBL2179718 0.89 LMNA (0.51) MAPTSDCBPSDC2LMNATP53
SCHEMBL2178224 0.87 DGAT1 (0.52) KDRSDCBPSDC2LMNATP53
SCHEMBL2178233 0.87 DGAT1 (0.52) KDRSDCBPSDC2LMNATP53
SCHEMBL2180590 0.86 DGAT1 (0.52) MEN1MAPTKMT2AKDRSDCBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT MEN1 3071/4885ALDH1A1 715/4885MAPT 116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.